- Home
- APA vs EXEL Comparison
APA vs EXEL Comparison
Compare APA & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | APA | EXEL |
|---|---|---|
| Founded | 1954 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 11.4B |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | APA | EXEL |
|---|---|---|
| Price | $35.91 | $43.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 23 | 21 |
| Target Price | $31.48 | ★ $46.45 |
| AVG Volume (30 Days) | ★ 9.5M | 2.0M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | ★ 75.77 | 57.95 |
| EPS | ★ 3.99 | 2.78 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $3.86 | $13.61 |
| Revenue Next Year | N/A | $13.13 |
| P/E Ratio | ★ $8.95 | $16.13 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.20 | $33.76 |
| 52 Week High | $45.66 | $48.74 |
Technical Indicators
Market Signals| Indicator | APA | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 43.81 | 49.78 |
| Support Level | $35.13 | $40.53 |
| Resistance Level | $45.66 | $44.32 |
| Average True Range (ATR) | 1.94 | 1.14 |
| MACD | -1.02 | 0.02 |
| Stochastic Oscillator | 23.51 | 30.48 |
Price Performance
Historical ComparisonAbout APA APA Corporation
APA Corp is an independent exploration and production company. It develops and produces crude oil, natural gas, and natural gas liquids. The company's business has oil and gas operations in four segments: Egypt, the North Sea, Suriname, and the U.S. The company generates the majority of its revenue from the U.S. reporting segment. The company also has exploration interests in Uruguay, Alaska, and other international locations.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.